To ensure rapid and sustainable access for patients to innovative approaches to the treatment of socially significant diseases, the production of oncology and autoimmune drugs will be localized in Kazakhstan.
This agreement was reached at the site of the III international pharmaceutical forum “Global Pharm” between the Ministry of Health of the Republic of Kazakhstan and the biotechnology company “BIOCAD” when concluding a Memorandum of Cooperation and Mutual Understanding.
BIOCAD is one of the largest biotechnological innovative companies in Russia, combining world-class research centers, modern pharmaceutical and biotechnological production, preclinical and clinical research that meets international standards. The company produces innovative drugs for the treatment of cancer and autoimmune diseases, and also develops original gene therapy drugs.
The transfer of the company's drug production technologies on the territory of Kazakhstan will increase the availability of highly effective therapy for patients and will give impetus to the development of the competitiveness and potential of the country's medical and pharmaceutical industry.
The purpose of the Memorandum is to ensure prompt and sustainable access for patients to innovative approaches to the treatment of socially significant diseases and to promote the development of an effective and sustainable system for protecting the health of citizens of Kazakhstan.
The parties intend to consider the possibility of implementing joint research projects, including conducting clinical trials of drugs.
The head of state has repeatedly noted the importance of cooperation with global players and technology transfer, instructing to increase the share of domestic medicines to 50%.
The international pharmaceutical forum “Global Pharm” rightfully retains its status as the most effective dialogue platform for identifying new development opportunities and searching for reliable business partnerships. During the forum, Kazakhstan signed five Memorandums of Cooperation with domestic and foreign companies.